Completion of SCIB1 cGMP Manufacture

Embargoed Release: 07:00hrs, Monday 2 November 2009

GB00B39J5N63

                             Scancell Holdings Plc                             

                    (`Scancell Holdings' or the `Company')                     

       Completion of cGMP manufacture for Scancell's SCIB1 Clinical Trial       

Scancell Holdings Plc, (PLUS:SCLP) the parent company of Scancell Limited
(`Scancell'), the developer of therapeutic cancer vaccines based on its
patented ImmunoBody® platform, is pleased to announce that the current Good
Manufacturing Practice (`cGMP') production of Scancell's SCIB1 DNA vaccine has
been successfully completed ahead of the planned clinical trials that are
expected to commence on schedule in H1 2010.

SCIB1 is being developed for the treatment of melanoma. The vaccine has been
developed using Scancell's patent-protected ImmunoBody® technology platform
that overcomes the current limitations of most cancer vaccines by generating
the high-avidity T-cells that kill cancer cells. Melanoma kills over 1,800
people every year in the UK, with over 130,000 new cases of the disease being
reported annually worldwide. Advanced melanoma currently has a very poor
prognosis with late stage (stage IV) disease having a median survival of
approximately 6 months.

The cGMP manufacturing was completed by AIM-Listed Cobra Biomanufacturing Plc
(AIM:CBF), the international manufacturer of biopharmaceuticals. The final
release of the product for SCIB1 clinical trials is anticipated mid-Q4 2009 and
will be undertaken by Cobra's in-house QP.

David Evans, Chairman of Scancell, commented:

"Cobra Biomanufacturing has done an excellent job manufacturing our SCIB1 DNA
vaccine on time and on budget. This is another important step forward towards
our goal of starting clinical trials with SCIB1 in the first half of 2010."

Simon Saxby, Chief Executive of Cobra Biomanufacturing said:

"It has been a pleasure to work with Scancell on the production of its SCIB1
vaccine. The two teams have worked closely together to make this a highly
successful project and we wish Scancell every success with their clinical
trials. The Cobra team look forward to working with Scancell in the future."

The Directors of the issuer accept responsibility for this announcement.

                                    -ENDS-                                     

For further information contact:

Professor Lindy Durrant         Scancell Holdings Plc    + 44 207 245 1100   
                                                                             
John Bick/Vikki Krause          Hansard Group            + 44 7515 922906    
                                                                             
Ross Andrews                    Zeus Capital             + 44 (0)161 831 1512

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1 is being developed for the
treatment of melanoma and will enter clinical trials in early 2010.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a DNA vaccine encoding a human antibody or fusion protein
engineered to express helper cell and CTL epitopes from tumour antigens
over-expressed by cancer cells. Antibodies are ideal vectors for carrying T
cell epitopes from tumour antigens as they can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of high avidity
and high frequency helper and CTL responses.

The ImmunoBody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.

About Cobra Biomanufacturing Plc:

Cobra Biomanufacturing Plc is a leading international manufacturer of
biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides
innovative manufacturing solutions to the biopharmaceutical industry covering
DNA, virus, cellular therapeutics and recombinant protein products.

Cobra has developed a range of unique, patented technologies, which underpin a
successful revenue generating contract manufacturing business.

www.cobrabio.com